|
Pseduorabies Subunit Glycoprotein C Vaccine |
Pseudorabies recombinant vector vaccine encoding gp50 and gII protein |
Pseudorabies recombinant vector vaccine encoding gp50 protein |
Pseudorabies virus gp50/gp63 mutant vaccine |
Pseudorabies virus UL50 mutant vaccine |
Pseudorabies virus US3 mutant vaccine |
Psuedorabies virus glycoprotein M mutant vaccine |
| Vaccine Information |
Vaccine Information |
Vaccine Information |
Vaccine Information |
Vaccine Information |
Vaccine Information |
Vaccine Information |
- Vaccine Ontology ID: VO_0004155
- Type: Subunit vaccine
- Status: Research
- UL44
gene engineering:
- Type: Recombinant protein preparation
- Description: Psuedorabies glycoprotein C was purified from pseudorabies infected cell lysates (Katayama et al., 1997).
- Detailed Gene Information: Click Here.
- Immunization Route: Intramuscular injection (i.m.)
|
- Vaccine Ontology ID: VO_0004156
- Type: Recombinant vector vaccine
- Status: Licensed
- gp50
gene engineering:
- Type: Recombinant vector construction
- Detailed Gene Information: Click Here.
- GII
gene engineering:
- Type: Recombinant vector construction
- Detailed Gene Information: Click Here.
- Vector: NYVAC vaccinia vector (Brockmeier and Mengeling, 1996).
- Immunization Route: Intramuscular injection (i.m.)
|
- Vaccine Ontology ID: VO_0004003
- Type: Recombinant vector vaccine
- Status: Research
- gp50
gene engineering:
- Type: Recombinant vector construction
- Detailed Gene Information: Click Here.
- Vector: NYVAC vaccinia vector (Brockmeier and Mengeling, 1996).
- Immunization Route: Intramuscular injection (i.m.)
|
- Type: Live, attenuated vaccine
- Status: Research
- Host Species as Laboratory Animal Model: Pig
- gp50
gene engineering:
- Type: Gene mutation
- Description: This gp50/gp63 mutant is from Suid herpesvirus 1 (Peeters et al., 1994).
- Detailed Gene Information: Click Here.
- gp63
gene engineering:
- Type: Gene mutation
- Description: This gp50/gp63 mutant is from Suid herpesvirus 1 (Peeters et al., 1994).
- Detailed Gene Information: Click Here.
- Immunization Route: Intramuscular injection (i.m.)
|
- Vaccine Ontology ID: VO_0002989
- Type: Live, attenuated vaccine
- Status: Research
- Host Species as Laboratory Animal Model: Pig
- UL50
gene engineering:
- Type: Gene mutation
- Description: This UL50 mutant is from Suid herpesvirus 1 (Jöns et al., 1997).
- Detailed Gene Information: Click Here.
- Immunization Route: intranasal immunization
|
- Vaccine Ontology ID: VO_0002990
- Type: Live, attenuated vaccine
- Status: Research
- Host Species as Laboratory Animal Model: Pig
- US3
gene engineering:
- Type: Gene mutation
- Description: This US3 mutant is from Suid herpesvirus 1 (Kimman et al., 1994).
- Detailed Gene Information: Click Here.
- Immunization Route: intranasal immunization
|
- Vaccine Ontology ID: VO_0002985
- Type: Live, attenuated vaccine
- Status: Research
- Host Species as Laboratory Animal Model: Pig
- glycoprotein M
gene engineering:
- Type: Gene mutation
- Description: This glycoprotein M mutant is from Pseudorabies virus (Dijkstra et al., 1997).
- Detailed Gene Information: Click Here.
- Immunization Route: intranasal immunization
|
| Host Response |
Host Response |
Host Response |
Host Response |
Host Response |
Host Response |
Host Response |
|
Pig Response
- Vaccination Protocol: Pigs of each group were immunized intramuscularly with one ml of the different trial vaccines at two week intervals. Control pigs were vaccinated with unifected cell lysate antigens (Katayama et al., 1997).
- Challenge Protocol: One week after immunization pigs were challenged intranasally with 10^6 TCID50 of PRV Yamagata S-81 strain (Katayama et al., 1997).
- Efficacy: Immunized pigs had a high (87.5%) rate of survival against lethal PRV challenge (Katayama et al., 1997).
|
Pig Response
- Vaccination Protocol: 4-6 wk old male pigs from a PRV negative herd were vaccinated intramuscularly with two injections in the thigh of 10^7 CCID50 of NYVAC/gp50gpII 4 weeks apart. The control group was not vaccinated (Brockmeier and Mengeling, 1996).
- Challenge Protocol: Challenge consisted of administering 10^8 PFU of Indiana-Funkhauser strain of PRV oranasally, 4 weeks after the 2nd immunization (Brockmeier and Mengeling, 1996).
- Efficacy: Vaccinated pigs were protected from PRV challenge (Brockmeier and Mengeling, 1996).
|
Pig Response
- Vaccination Protocol: 4-6 wk old male pigs from a PRV negative herd were vaccinated intramuscularly with two injections in the thigh of 10^7 CCID50 of NYVAC/gpSO 4 weeks apart. The control group was not vaccinated (Brockmeier and Mengeling, 1996).
- Challenge Protocol: Challenge consisted of administering 10^8 PFU of Indiana-Funkhauser strain of PRV oranasally, 4 weeks after the 2nd immunization (Brockmeier and Mengeling, 1996).
- Efficacy: Vaccinated pigs were protected from PRV challenge (Brockmeier and Mengeling, 1996).
|
Pig Response
- Persistence: A gp50/gp63 mutant is attenuated in pigs (Peeters et al., 1994).
- Efficacy: A gp50/gp63 mutant vaccine induces protection in pigs from challenge with wild type Pseudorabies virus (Peeters et al., 1994).
|
Pig Response
- Persistence: A UL50 mutant is attenuated in pigs (Jöns et al., 1997).
- Efficacy: A UL50 mutant induces protection in pigs from challenge with wild type Pseudorabies virus (Jöns et al., 1997).
|
Pig Response
- Persistence: A US3 mutant is attenuated in pigs (Kimman et al., 1994).
- Efficacy: A US3 mutant induces complete protection in pigs from challenge with wild type Pseudorabies virus (Kimman et al., 1994).
|
Pig Response
- Persistence: A glycoprotein M mutant is attenuated in piglets (Dijkstra et al., 1997).
- Efficacy: A glycoprotein M mutant induces protection in piglets from challenge with wild type Pseudorabies virus (Dijkstra et al., 1997).
|
| References |
References |
References |
References |
References |
References |
References |
Katayama et al., 1997: Katayama S, Okada N, Yoshiki K, Okabe T, Shimizu Y. Protective effect of glycoprotein gC-rich antigen against pseudorabies virus. The Journal of veterinary medical science / the Japanese Society of Veterinary Science. 1997; 59(8); 657-663. [PubMed: 9300361].
|
Brockmeier and Mengeling, 1996: Brockmeier SL, Mengeling WL. Comparison of the protective response induced by NYVAC vaccinia recombinants expressing either gp50 or gII and gp50 of pseudorabies virus. Canadian journal of veterinary research = Revue canadienne de recherche veterinaire. 1996; 60(4); 315-317. [PubMed: 8904669].
|
Brockmeier and Mengeling, 1996: Brockmeier SL, Mengeling WL. Comparison of the protective response induced by NYVAC vaccinia recombinants expressing either gp50 or gII and gp50 of pseudorabies virus. Canadian journal of veterinary research = Revue canadienne de recherche veterinaire. 1996; 60(4); 315-317. [PubMed: 8904669].
|
Peeters et al., 1994: Peeters B, Bouma A, de Bruin T, Moormann R, Gielkens A, Kimman T. Non-transmissible pseudorabies virus gp50 mutants: a new generation of safe live vaccines. Vaccine. 1994; 12(4); 375-380. [PubMed: 8178562].
|
Jöns et al., 1997: Jöns A, Gerdts V, Lange E, Kaden V, Mettenleiter TC. Attenuation of dUTPase-deficient pseudorabies virus for the natural host. Veterinary microbiology. 1997; 56(1-2); 47-54. [PubMed: 9228681].
|
Kimman et al., 1994: Kimman TG, De Wind N, De Bruin T, de Visser Y, Voermans J. Inactivation of glycoprotein gE and thymidine kinase or the US3-encoded protein kinase synergistically decreases in vivo replication of pseudorabies virus and the induction of protective immunity. Virology. 1994; 205(2); 511-518. [PubMed: 7975253].
|
Dijkstra et al., 1997: Dijkstra JM, Gerdts V, Klupp BG, Mettenleiter TC. Deletion of glycoprotein gM of pseudorabies virus results in attenuation for the natural host. The Journal of general virology. 1997; 78 ( Pt 9); 2147-2151. [PubMed: 9292000].
|
